Milrinone increases flow in coronary artery bypass grafts after cardiopulmonary bypass: a prospective, randomized, double-blind, placebo-controlled study. 2009

Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
Department of Cardiothoracic Surgery and Anesthesiology, Orebro University Hospital, Orebro, Sweden. mikael.arbeus@orebroll.se

OBJECTIVE To compare the effects of a bolus of milrinone, 50 microg/kg, versus placebo on flow in coronary artery bypass grafts after cardiopulmonary bypass (CPB). METHODS A prospective, randomized, double-blind study. METHODS A university hospital. METHODS Forty-four patients with stable angina and left ventricular ejection fraction >30% scheduled for elective coronary artery bypass graft (CABG) surgery were included. METHODS Patients were randomized to receive 50 microg/kg of milrinone (n = 22) or placebo (n = 22) after aortic declamping. RESULTS The flow in coronary artery bypass grafts was measured with a transit time flow meter at 10 minutes and 30 minutes after termination of CPB. The hemodynamic evaluation included transesophageal echocardiography, mean arterial pressure (MAP), heart rate, and intracavitary measurement of left ventricular end-diastolic pressure (LVEDP). The flow in the saphenous vein grafts was significantly higher in the milrinone group when compared with the placebo group both at 10 and 30 minutes after termination of CPB (p < 0.001). At 10 minutes, the flow was 64.5 +/- 37.4 mL/min (mean +/- standard deviation) and 43.6 +/- 25.7 mL/min in nonsequential vein grafts for milrinone and placebo, respectively. Corresponding values at 30 minutes were 54.8 +/- 29.9 mL/min and 35.3 +/- 22.4 mL/min. The left internal thoracic artery (LITA) flow was higher in the milrinone group but did not reach statistical significance. The fractional area change was higher, and the MAP and calculated pressure gradient (MAP-LVEDP) were lower at 10 minutes in the milrinone group. CONCLUSIONS Milrinone significantly increases the flow in anastomosed saphenous vein grafts after CPB, and has beneficial effects on left ventricular function.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
March 2000, The Journal of thoracic and cardiovascular surgery,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
February 2002, Journal of cardiothoracic and vascular anesthesia,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
October 1993, Critical care medicine,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
April 1996, Anesthesia and analgesia,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
October 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
July 2012, The Journal of thoracic and cardiovascular surgery,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
May 2013, Obesity (Silver Spring, Md.),
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
July 1998, Journal of cardiovascular pharmacology and therapeutics,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
July 2020, Journal of cardiovascular pharmacology and therapeutics,
Mikael Arbeus, and Birger Axelsson, and Orjan Friberg, and Anders Magnuson, and Lennart Bodin, and Jan Hultman
November 2005, British journal of anaesthesia,
Copied contents to your clipboard!